TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MSTR
Strategy
-- 304.000 SMCI
Super Micro Computer
-- 42.150 
Update
$Nektar Therapeutics (NKTR.US)$ Data From Nektar's Multiple Phase 1b Studies In Inflammatory Skin Conditions Demonstrate Durable Dose-dependent Improvements In Physician-assessed Disease Activity And Patient-reported Outcomes
Benzinga· 1 min ago
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -
Benzinga· 1 min ago
- Data from multiple Phase 1b studies in inflammatory skin conditions demonstrate durable dose-dependent improvements in physician-assessed disease activity and patient-reported outcomes -
- Biomarker analyses demonstrate plurality of Treg-mediated pathways with potential effect on tissue resident memory T cell populations resulting in sustained efficacy seen in the antigen challenged mouse model and in clinical trials -
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment